<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39135051</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1476-9255</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of inflammation (London, England)</Title><ISOAbbreviation>J Inflamm (Lond)</ISOAbbreviation></Journal><ArticleTitle>Evidence of aberrant anti-epstein-barr virus antibody response, though no viral reactivation, in people with post-stroke fatigue.</ArticleTitle><Pagination><StartPage>30</StartPage><MedlinePgn>30</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">30</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12950-024-00402-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Fatigue is a common complication of stroke that has a significant impact on quality of life. The biological mechanisms that underly post-stroke fatigue are currently unclear, however, reactivation of latent viruses and their impact on systemic immune function have been increasingly reported in other conditions where fatigue is a predominant symptom. Epstein-Barr virus (EBV) in particular has been associated with fatigue, including in long-COVID and myalgic encephalomyelitis/chronic fatigue syndrome, but has not yet been explored within the context of stroke.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">We performed an exploratory analysis to determine if there is evidence of a relationship between EBV reactivation and post-stroke fatigue.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In a chronic ischemic stroke cohort (&gt;&#x2009;5 months post-stroke), we assayed circulating EBV by qPCR and measured the titres of anti-EBV antibodies by ELISA in patients with high fatigue (FACIT-F&#x2009;&lt;&#x2009;40) and low fatigue (FACIT-F&#x2009;&gt;&#x2009;41). Statistical analysis between two-groups were performed by t-test when normally distributed according to the Shapiro-Wilk test, by Mann-Whitney test when the data was not normally distributed, and by Fisher's exact test for categorical data.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed a similar incidence of viral reactivation between people with low versus high levels of post-stroke fatigue (5 of 22 participants (24%) versus 6 of 22 participants (27%)). Although the amount of circulating EBV was similar, we observed an altered circulating anti-EBV antibody profile in participants with high fatigue, with reduced IgM against the Viral Capsid Antigen (2.244&#x2009;&#xb1;&#x2009;0.926 vs. 3.334&#x2009;&#xb1;&#x2009;2.68; P&#x2009;=&#x2009;0.031). Total IgM levels were not different between groups indicating this effect was specific to anti-EBV antibodies (3.23&#x2009;&#xd7;&#x2009;10<sup>5</sup> &#xb1; 4.44&#x2009;&#xd7;&#x2009;10<sup>4</sup> high fatigue versus 4.60&#x2009;&#xd7;&#x2009;10<sup>5</sup> &#xb1; 9.28&#x2009;&#xd7;&#x2009;10<sup>4</sup> low fatigue; P&#x2009;=&#x2009;0.288).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These data indicate that EBV is not more prone to reactivation during chronic stroke recovery in those with post-stroke fatigue. However, the dysregulated antibody response to EBV may be suggestive of viral reactivation at an earlier stage after stroke.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mouat</LastName><ForeName>Isobel C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Centre for Inflammation Research, Institute for Regeneration and Repair South, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aslan</LastName><ForeName>Alperen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McColl</LastName><ForeName>Barry W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>UK Dementia Research Institute, Centre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allan</LastName><ForeName>Stuart M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Geoffrey Jefferson Brain Research Centre, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Neuroscience, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Craig J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Geoffrey Jefferson Brain Research Centre, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckwalter</LastName><ForeName>Marion S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCulloch</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Inflammation Research, Institute for Regeneration and Repair South, University of Edinburgh, Edinburgh, UK. laura.mcculloch@ed.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>19PABHI34580007</GrantID><Agency>American Heart Institute / Allen Frontiers Group Brain Health Award</Agency><Country/></Grant><Grant><GrantID>220755/Z/20/Z</GrantID><Agency>Wellcome Sir Henry Dale Fellowship</Agency><Country/></Grant><Grant><GrantID>19CVD01</GrantID><Agency>Leducq Stroke-IMPaCT Transatlantic Network of Excellence</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Inflamm (Lond)</MedlineTA><NlmUniqueID>101232234</NlmUniqueID><ISSNLinking>1476-9255</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Epstein-Barr virus</Keyword><Keyword MajorTopicYN="N">Fatigue</Keyword><Keyword MajorTopicYN="N">Ischaemic stroke</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>12</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39135051</ArticleId><ArticleId IdType="pmc">PMC11321160</ArticleId><ArticleId IdType="doi">10.1186/s12950-024-00402-0</ArticleId><ArticleId IdType="pii">10.1186/s12950-024-00402-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhan J, Zhang P, Wen H, Wang Y, Yan X, Zhan L, et al. Global prevalence estimates of poststroke fatigue: a systematic review and meta-analysis. Int J Stroke. 2023;18(9):1040&#x2013;50. 10.1177/17474930221138701</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17474930221138701</ArticleId><ArticleId IdType="pubmed">36314998</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill G, Regan S, Francis R. Research priorities to improve stroke outcomes. Lancet Neurol. 2022;21(4):312&#x2013;3. 10.1016/S1474-4422(22)00044-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(22)00044-8</ArticleId><ArticleId IdType="pmc">PMC8926410</ArticleId><ArticleId IdType="pubmed">35305334</ArticleId></ArticleIdList></Reference><Reference><Citation>English C, Simpson DB, Billinger SA, Churilov L, Coupland KG, Drummond A et al. A roadmap for research in post-stroke fatigue: consensus-based core recommendations from the third stroke recovery and rehabilitation roundtable. Int J Stroke. 2023:17474930231189135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10811972</ArticleId><ArticleId IdType="pubmed">37424273</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Cheng S, Zhang Z, Wang C, Wang A, Zhu W. Related risk factors associated with post-stroke fatigue: a systematic review and meta-analysis. Neurol Sci. 2021;42(4):1463&#x2013;71. 10.1007/s10072-020-04633-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04633-w</ArticleId><ArticleId IdType="pubmed">32813167</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivard A, Lillicrap T, Krishnamurthy V, Holliday E, Attia J, Pagram H, et al. MIDAS (Modafinil in debilitating fatigue after stroke): a randomized, double-blind, placebo-controlled, cross-over trial. Stroke. 2017;48(5):1293&#x2013;8. 10.1161/STROKEAHA.116.016293</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.116.016293</ArticleId><ArticleId IdType="pmc">PMC5404401</ArticleId><ArticleId IdType="pubmed">28404841</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox JR, Dhodapkar RM, Lu P, Gehlhausen JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. 2023;623(7985):139&#x2013;48. 10.1038/s41586-023-06651-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06651-y</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Shikova E, Reshkova V, Kumanova &#x410;, Raleva S, Alexandrova D, Capo N, Cytomegalovirus, et al. Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic &#x435;ncephalomyelitis/chronic fatigue syndrome. J Med Virol. 2020;92(12):3682&#x2013;8.10.1002/jmv.25744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25744</ArticleId><ArticleId IdType="pmc">PMC7687071</ArticleId><ArticleId IdType="pubmed">32129496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481&#x2013;92. 10.1056/NEJM200008173430707</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200008173430707</ArticleId><ArticleId IdType="pubmed">10944566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72(10):651&#x2013;8. 10.1136/jclinpath-2019-205822</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jclinpath-2019-205822</ArticleId><ArticleId IdType="pubmed">31315893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru Y, Zhang X, Song T, Ding Y, Zhu Z, Fan Y, et al. Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation: multifactorial impact on transplant outcomes. Bone Marrow Transpl. 2020;55(9):1754&#x2013;62.10.1038/s41409-020-0831-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41409-020-0831-7</ArticleId><ArticleId IdType="pubmed">32066862</ArticleId></ArticleIdList></Reference><Reference><Citation>San-Juan R, Comoli P, Caillard S, Moulin B, Hirsch HH, Meylan P. Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):109&#x2013;18. 10.1111/1469-0691.12534</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1469-0691.12534</ArticleId><ArticleId IdType="pubmed">24475976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferbas J, Rahman MA, Kingsley LA, Armstrong JA, Ho M, Zhou SY, et al. Frequent oropharyngeal shedding of Epstein-Barr virus in homosexual men during early HIV infection. Aids. 1992;6(11):1273&#x2013;8. 10.1097/00002030-199211000-00006</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-199211000-00006</ArticleId><ArticleId IdType="pubmed">1335273</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens SJ, Blank BS, Smits PH, Meenhorst PL, Middeldorp JM. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. Aids. 2002;16(7):993&#x2013;1001. 10.1097/00002030-200205030-00005</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-200205030-00005</ArticleId><ArticleId IdType="pubmed">11953465</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser R, Pearson GR, Jones JF, Hillhouse J, Kennedy S, Mao HY, et al. Stress-related activation of Epstein-Barr virus. Brain Behav Immun. 1991;5(2):219&#x2013;32. 10.1016/0889-1591(91)90018-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0889-1591(91)90018-6</ArticleId><ArticleId IdType="pubmed">1654167</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M. CD4&#x2009;+&#x2009;cytotoxic T cells involved in the development of EBV-associated diseases. Pathogens. 2022;11(8).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330826</ArticleId><ArticleId IdType="pubmed">35894054</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevang B, Wyller VBB, Mollnes TE, Pedersen M, Asprusten TT, Michelsen A, et al. Lasting immunological imprint of primary Epstein-Barr virus infection with associations to chronic low-grade inflammation and fatigue. Front Immunol. 2021;12:715102. 10.3389/fimmu.2021.715102</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.715102</ArticleId><ArticleId IdType="pmc">PMC8721200</ArticleId><ArticleId IdType="pubmed">34987499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann S, Harms H, Ulm L, Nabavi DG, Mackert B-M, Schmehl I, et al. Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia &#x2013; the PREDICT study. J Cereb Blood Flow Metab. 2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718319</ArticleId><ArticleId IdType="pubmed">27733675</ArticleId></ArticleIdList></Reference><Reference><Citation>Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2194193</ArticleId><ArticleId IdType="pubmed">12939340</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulloch L, Smith CJ, McColl BW. Adrenergic-mediated loss of splenic marginal zone B cells contributes to infection susceptibility after stroke. Nat Commun. 2017;8:15051. 10.1038/ncomms15051</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms15051</ArticleId><ArticleId IdType="pmc">PMC5399306</ArticleId><ArticleId IdType="pubmed">28422126</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a stroke risk factor and determinant of outcome after stroke. Stroke. 2020;51(10):3156&#x2013;68. 10.1161/STROKEAHA.120.030429</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.120.030429</ArticleId><ArticleId IdType="pmc">PMC7530056</ArticleId><ArticleId IdType="pubmed">32897811</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung YC, Tu HP, Wu MK, Kuo KL, Su YF, Lu YY, et al. Higher risk of herpes zoster in stroke patients. PLoS ONE. 2020;15(2):e0228409. 10.1371/journal.pone.0228409</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0228409</ArticleId><ArticleId IdType="pmc">PMC6999860</ArticleId><ArticleId IdType="pubmed">32017810</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertrand L, M&#xe9;roth F, Tournebize M, Leda AR, Sun E, Toborek M. Targeting the HIV-infected brain to improve ischemic stroke outcome. Nat Commun. 2019;10(1):2009. 10.1038/s41467-019-10046-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10046-x</ArticleId><ArticleId IdType="pmc">PMC6494822</ArticleId><ArticleId IdType="pubmed">31043599</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumenyuk &#x410;, Motorna N, Rybalko S, Savosko S, Sokurenko L, Starosyla D, et al. Development of herpetic infection associated with stroke and its correction with acyclovir. Curr Issues Pharm Med Sci. 2017;30(1):20&#x2013;3.10.1515/cipms-2017-0004</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cipms-2017-0004</ArticleId></ArticleIdList></Reference><Reference><Citation>Drag LL, Mlynash M, Nassar H, Osborn E, Kim DE, Angst MS, et al. A longitudinal study of the post-stroke immune response and cognitive functioning: the StrokeCog study protocol. BMC Neurol. 2020;20(1):313. 10.1186/s12883-020-01897-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-020-01897-9</ArticleId><ArticleId IdType="pmc">PMC7448308</ArticleId><ArticleId IdType="pubmed">32847540</ArticleId></ArticleIdList></Reference><Reference><Citation>Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63&#x2013;74. 10.1016/S0885-3924(96)00274-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0885-3924(96)00274-6</ArticleId><ArticleId IdType="pubmed">9095563</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan PW, Bode RK, Min Lai S, Perera S. Rasch analysis of a new stroke-specific outcome scale: the stroke impact scale. Arch Phys Med Rehabil. 2003;84(7):950&#x2013;63. 10.1016/S0003-9993(03)00035-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0003-9993(03)00035-2</ArticleId><ArticleId IdType="pubmed">12881816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasreddine ZS, Phillips NA, B&#xe9;dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695&#x2013;9. 10.1111/j.1532-5415.2005.53221.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1532-5415.2005.53221.x</ArticleId><ArticleId IdType="pubmed">15817019</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt Z, Lai JS, Rao D, Heinemann AW, Bill A, Cella D. Measurement of fatigue in cancer, stroke, and HIV using the functional assessment of chronic illness therapy - fatigue (FACIT-F) scale. J Psychosom Res. 2013;74(1):64&#x2013;8. 10.1016/j.jpsychores.2012.10.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2012.10.011</ArticleId><ArticleId IdType="pmc">PMC3534851</ArticleId><ArticleId IdType="pubmed">23272990</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith CJ, Emsley HCA, Gavin CM, Georgiou RF, Vail A, Barberan EM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;4(1):2. 10.1186/1471-2377-4-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2377-4-2</ArticleId><ArticleId IdType="pmc">PMC331413</ArticleId><ArticleId IdType="pubmed">14725719</ArticleId></ArticleIdList></Reference><Reference><Citation>Brengel-Pesce K, Morand P, Schmuck A, Bourgeat MJ, Buisson M, Bargu&#xe8;s G, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol. 2002;66(3):360&#x2013;9. 10.1002/jmv.2153</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.2153</ArticleId><ArticleId IdType="pubmed">11793388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopal MR, Thomson BJ, Fox J, Tedder RS, Honess RW. Detection by PCR of HHV-6 and EBV DNA in blood and oropharynx of healthy adults and HIV-seropositives. Lancet. 1990;335(8705):1598&#x2013;9. 10.1016/0140-6736(90)91433-B</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(90)91433-B</ArticleId><ArticleId IdType="pubmed">1972522</ArticleId></ArticleIdList></Reference><Reference><Citation>Haque T, Crawford DH. PCR amplification is more sensitive than tissue culture methods for Epstein-Barr virus detection in clinical material. J Gen Virol. 1997;78(Pt 12):3357&#x2013;60. 10.1099/0022-1317-78-12-3357</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-12-3357</ArticleId><ArticleId IdType="pubmed">9400988</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. 2007;42(6):563&#x2013;70. 10.1016/j.exger.2007.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2007.01.005</ArticleId><ArticleId IdType="pmc">PMC1992441</ArticleId><ArticleId IdType="pubmed">17337145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrhofer J, Graninger M, Lettenmaier L, Schweighardt J, Gentile SA, Koidl L, et al. Association between Epstein-Barr-Virus reactivation and development of Long-COVID fatigue. Allergy. 2023;78(1):297&#x2013;9. 10.1111/all.15471</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15471</ArticleId><ArticleId IdType="pmc">PMC9538037</ArticleId><ArticleId IdType="pubmed">35950630</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A, Engelmann I, Moreau AS, Garcia B, Six S, El Kalioubie A, et al. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now. 2021;51(3):296&#x2013;9. 10.1016/j.idnow.2021.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;e9520. 10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorp WF, Vermeij JD, Hilkens NA, Brouwer MC, Algra A, van der Worp HB, et al. Development and internal validation of a prediction rule for post-stroke infection and post-stroke pneumonia in acute stroke patients. Eur Stroke J. 2018;3(2):136&#x2013;44. 10.1177/2396987318764519</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2396987318764519</ArticleId><ArticleId IdType="pmc">PMC5992742</ArticleId><ArticleId IdType="pubmed">29900413</ArticleId></ArticleIdList></Reference><Reference><Citation>McCulloch L, Allan SM, Smith CJ, McColl BW. Interleukin-1 receptor antagonist treatment in acute ischaemic stroke does not alter systemic markers of anti-microbial defence. bioRxiv. 2019:587881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6820822</ArticleId><ArticleId IdType="pubmed">31700615</ArticleId></ArticleIdList></Reference><Reference><Citation>Paciaroni M, Acciarresi M. Poststroke fatigue. Stroke. 2019;50(7):1927&#x2013;33. 10.1161/STROKEAHA.119.023552</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.119.023552</ArticleId><ArticleId IdType="pubmed">31195940</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomasini RL, Pereira DS, Pereira FSM, Mateo EC, Mota TN, Guimar&#xe3;es GG, et al. Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS ONE. 2017;12(7):e0180841. 10.1371/journal.pone.0180841</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0180841</ArticleId><ArticleId IdType="pmc">PMC5507269</ArticleId><ArticleId IdType="pubmed">28700679</ArticleId></ArticleIdList></Reference><Reference><Citation>Sausen DG, Bhutta MS, Gallo ES, Dahari H, Borenstein R. Stress-induced Epstein-Barr virus reactivation. Biomolecules. 2021;11(9).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8470332</ArticleId><ArticleId IdType="pubmed">34572593</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin &#xc5;, Taft C, Lundgren-Nilsson &#xc5;, Dencker A. Minimal important differences for fatigue patient reported outcome measures&#x2014;a systematic review. BMC Med Res Methodol. 2016;16(1):62. 10.1186/s12874-016-0167-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0167-6</ArticleId><ArticleId IdType="pmc">PMC4937582</ArticleId><ArticleId IdType="pubmed">27387456</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasa S, Nora-Krukle Z, Henning N, Eliassen E, Shikova E, Harrer T, et al. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med. 2018;16(1):268. 10.1186/s12967-018-1644-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1644-y</ArticleId><ArticleId IdType="pmc">PMC6167797</ArticleId><ArticleId IdType="pubmed">30285773</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>